Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Authors / James Strachan

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

  • Contributions

Automating Cell Therapy Manufacturing

September 17, 2021

Fabian Gerlinghaus, CoFounder and Chief Executive Officer at Cellares, believes he can make autologous cell therapy a realistic proposition for solid tumors by closing and automating manufacturing

1 min read

Automating Cell Therapy Manufacturing

Unleashing Cellular Potential

August 6, 2021

Karin Schmitt, Chief Business Officer at Mogrify, explains how epigenetic switches are being used to identify the optimal culture conditions required to support the conversion and maintenance of any clinically valuable cell type

1 min read

Unleashing Cellular Potential

Completing the Cell Therapy Revolution

August 30, 2021

With no specific antigens available and a highly immunosuppressive microenvironment with little blood flow, how will researchers tackle solid tumors and bring cell therapy to millions?

1 min read

Completing the Cell Therapy Revolution

Understanding the Three Levels of Genetic Medicine

July 2, 2021

ASC Therapeutics is using a new type of stem cell derived from human placenta to treat graft-versus-host disease, as well as tackling hemophilia with gene and CRISPR therapies. To find out more, we speak with Chief Medical Officer Oscar Segurado, who also stresses the importance of helping patients understand the difference between gene therapy and different kinds of gene editing involving CRISPR.

1 min read

Understanding the Three Levels of Genetic Medicine

COVID-19: Inside the UK's Vaccine Taskforce

July 14, 2021

Hundreds of millions of doses secured, the first approval, and one of the fastest vaccination programs in the world. How did the UK do it?

1 min read

COVID-19: Inside the UK's Vaccine Taskforce

What's New from The Cell + Gene Curator?

July 13, 2021

History made as CAR T comes to China, bad news for Biogen and Tmunity, and the first reported case of partial functional recovery in a neurodegenerative disease after optogenetic therapy… What’s new from the Cell + Gene Curator?

1 min read

What's New from The Cell + Gene Curator?

People, Process, Product: Lessons Learned with Antoinette Gawin

July 23, 2021

Antoinette Gawin, President and CEO of Terumo Blood and Cell Technologies, explains how a random act of kindness set her on the path to becoming a VP in her 20s. Antoinette shares her lessons learned overcoming adversity to succeed in finance, utilities, M&A and – finally – cell and gene therapy.

1 min read

People, Process, Product: Lessons Learned with Antoinette Gawin

Watching the Future

July 28, 2021

Sitting Down With… Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER) at the FDA, USA

1 min read

Watching the Future

What's New from the Cell + Gene Curator?

June 11, 2021

Gene therapy’s “single most remarkable achievement,” CARs for solid tumors and plenty of new collaborations… What’s new from the Cell + Gene Curator?

1 min read

What's New from the Cell + Gene Curator?

How to Plug the Skills Gap

June 30, 2021

Experts from the BIA got together to discuss how the UK’s biotechnology industry can capitalize on recent investment and post-COVID-19 public appreciation to attract and train more people

1 min read

How to Plug the Skills Gap

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.